Sarah Roden's Opinion & Analysis
A complete archive of Sarah Roden's articles, including current analysis & opinion.
Aerie Pharmace (NASDAQ:AERI) shares shot up 56% to $20.75 in pre-market trading after the FDA agreed to allow Aerie to change the primary endpoint of its second Phase 3 trial of Rhopressa, an eye drop...
By Sarah Roden Facebook Inc (NASDAQ:FB) is constantly innovating and it doesn’t look like the social media giant is slowing down anytime soon. Recently, Facebook announced a new partnership...
Micron Technology (NASDAQ:MU) shares fell -3.30% in pre-market trading to $24.30 after Morgan Stanley) analyst Joseph Moore downgraded the stock from Equal-Weight to underweight and lowered his price...
The height of earnings season has passed, but companies posting quarterly earnings this week are still seeing the impact of trends such as a strong U.S. dollar and growing popularity of Cloud...
Lululemon athletica inc (NASDAQ:LULU) has faced its challenges in the past, from offensive comments made by its CEO to a massive recall on a pair of unintentionally see-through yoga pants. However, it...
CTI BioPharma Corp (NASDAQ:CTIC) shares increased 9.6% to $2.16 in pre-market trading after the pharmaceutical company announced that it has revised its current loan agreement with Hercules Technology...
Advanced Micro Devices Inc (NASDAQ:AMD) shares are up 2.60% in pre-market trading to $2.37 after pricing for the semiconductor company’s entire Radeon 300 series was leaked. Allegedly, the least...
Last week, Facebook Inc. (NASDAQ:FB) announced new initiatives to monetize Instagram. Facebook bought the photo-sharing platform in 2012 for approximately $1 billion in cash and stock.Instagram first...
MannKind Corporation (NASDAQ:MNKD) shares increased more than 2% in pre-market trading to $6.25 after Shaunak Deepak, an analyst at Jefferies, reiterated a Buy rating on the stock with a $9 price...
On June 2, Wedbush analyst Liana Moussatos published a list of upcoming catalysts for emerging pharmaceuticals, specifically for Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Receptos Inc...